Roles
- Professor of Clinical Medicine
- Co-Leader Gastrointestinal Cancers Site Disease Group, SCCC
- Associate Director for Clinical Research, Sylvester Pancreatic Cancer Research Institute
-
Biography
I am a board-certified medical oncologist with a primary clinical and research focus in gastrointestinal (GI) cancers with 13 years of post-fellowship academic experience in this area. At the University of Miami's NCI-designated Sylvester Comprehensive Cancer Center, I am an Associate Professor in the Department of Medicine and the co-director of the GI cancer site disease group where I oversee, organize, and prioritize the clinical trials portfolio for GI malignancies. -
Education & Training
Education
Post Graduate Training
-
Honors & Awards
-
Teaching Interests
Pancreatic Cancer. -
Research Interests
Dr. Hosein is a clinical researcher focused on Gastrointestinal Cancers. He has been the principal investigator for multiple phase I and II clinical trials for patients with liver and pancreatic cancers conducted at the Sylvester Comprehensive Cancer Center. He has also participated as a co-investigator in national phase III clinical trials in pancreatic and colorectal cancers. His primary research interest is in neoadjuvant therapy for patients with localized pancreatic cancer, and novel therapies for metastatic pancreatic cancer. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Pancreatic Cancer Vaccine Findings Spur New V Foundation-Funded Research at Sylvester Comprehensive Cancer Center
PanCAN Funds Sylvester Study of Blood Test for Pancreatic Cancer
FDA Approval Opens New Chapter in Pancreatic Cancer Treatment
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 22 clinical trials.
-
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
- Principal Investigator: Peter Hosein
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
To compare the effect of treatment with daraxonrasib following completion of neoadjuvant and/or adjuvant chemotherapy in patients with resected PDAC versus standard of care observation on: DFS (per Investigator). To compare the effect of treatment withdaraxonrasib following completion of neoadjuvant and/or adjuvant chemotherapy in patients with resected PDAC versus standard of care observation on: OS.
- Principal Investigator: Peter Hosein
- Study Phase: Phase III
- Enrollment Status: Open
-
Provide early access to Daraxonrasib for patients at UM with pancreatic cancer.
- Principal Investigator: Peter Hosein
- Study Phase: Other
- Enrollment Status: Not Accepting
-
This Study is being done to assess the safety and the effects of the Study Drug (INCB161734) when given together with chemotherapy, compared to a placebo plus chemotherapy. The study is for people with metastatic PDAC with a KRAS G12D mutation, who have not received any treatment for their metastatic disease.
- Principal Investigator: Peter Hosein
- Study Phase: Phase III
- Enrollment Status: Open
-
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)
- Principal Investigator: Peter Hosein
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Principal Investigator: Peter Hosein
- Study Phase: Phase 2
- Enrollment Status: Closed
-
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
- Principal Investigator: Peter Hosein
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
- Principal Investigator: Peter Hosein
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
- Principal Investigator: Peter Hosein
- Study Phase: Phase 3
- Enrollment Status: Closed
-
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Principal Investigator: Peter Hosein
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The purpose of this study is to determine what is the highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients, what is the highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients, and what is the highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.
- Principal Investigator: Peter Hosein
- Study Phase: Phase I
- Enrollment Status: Open
-
To assess the safety and tolerability of ELI-002 7P as adjuvant therapy for subjects with KRAS/NRAS mutated solid tumors who have minimal residual disease (MRD) identified using either ctDNA or a serum tumor biomarker
- Principal Investigator: Peter Hosein
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Principal Investigator: Peter Hosein
- Study Phase: Phase 3
- Enrollment Status: Closed
-
To evaluate the safety and tolerability of[177Lu]Lu FAP 2286 and determine the RP2D in combination with mFOLFIRNOX in PDAC and RP2D in combination with nab-paclitaxel in NSCLC (Phase 2 dose escalation for combination therapy). To assess image quality of [68Ga]Ga FAP 2286 PET scans. Assess difference between baseline [68Ga]Ga FAP 2286 PET scan and PET scan performed after the last dose of [177Lu]Lu FAP 2286.
- Principal Investigator: Peter Hosein
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
The purpose of this program is to provide access to an investigational treatment called ELI-002 7P for patients who may benefit from receiving and for whom no alternative/standard treatment or other clinical trial option is available in the judgment of your treating physician.
- Principal Investigator: Peter Hosein
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
The purpose of this study is to find out if KQB548 is a safe and tolerable treatment for solid tumor cancer. KQB548 is a drug that blocks a process in the body that cancer cells use to grow. By blocking that process, it may prevent your cancer cells from growing and spreading. These drugs will be tested at different strengths (doses) to find out which dose is safe and tolerable.
- Principal Investigator: Peter Hosein
- Study Phase: Phase I
- Enrollment Status: Open
-
This purpose of this study is to provide access to a cancer vaccine for pancreatic cancer that is not yet approved for commercial use. The vaccine has already been shown to be safe and there is a strong scientific rationale to offer it to this patient on an expanded access program.
- Principal Investigator: Peter Hosein
- Study Phase: N/A
- Enrollment Status: Closed
-
In the RAS G12-mutant population (referred toas RAS G12 population):• To compare the effect of treatment withRMC-6236 versus Investigator’s choice ofstandard therapy on:Progressionfree survival (PFS)Overallsurvival (OS)• PFS is defined as the time fromrandomization until disease progression ordeath from any cause, whichever occurs first.Progression is per RECIST v1.1 and asassessed by BICR• OS is defined as the time from randomizationuntil death from any causeTo compare the effect of treatment withRMC-6236 versus Investigator’s choice ofstandard therapy on:PFSOS
- Principal Investigator: Peter Hosein
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
The purposes of this study are to determine the best dose of TAC01-CLDN18.2 for treating adults with Claudin 18.2 positive cancer, to understand the side effects that people may have when they are treated with TAC01-CLDN18.2, and to study how well TAC01-CLDN18.2 works against Claudin 18.2 positive cancer.
- Principal Investigator: Peter Hosein
- Study Phase: Phase I/II
- Enrollment Status: Closed
-
To determine the recommended phase II dose (RP2RD) of trametinib, ruxolitinib, and retifanlimab (TR2) in patients with metastatic PDAC.
- Principal Investigator: Peter Hosein
- Study Phase: Phase I
- Enrollment Status: Closed
-
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- Principal Investigator: Peter Hosein
- Study Phase: Phase 2
- Enrollment Status: Open
-
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
- Principal Investigator: Peter Hosein
- Study Phase: Phase 2
- Enrollment Status: Not Accepting